A study to assess the therapeutic effect of enalapril on olanzapine induced metabolic syndrome in wistar rats

Avinash Arivazhahan, Laxminarayana Kurady Bairy, Veena Nayak, Sushil Kiran Kunder

Research output: Contribution to journalArticle

Abstract

Introduction: Metabolic Syndrome (MS) is a complex of risk factors for the development of cardiovascular complications and Type 2 Diabetes Mellitus (DM). Pharmacological management of the condition is complex, as multiple drug groups have to be used, as the syndrome itself is multi faceted. Angiotensin Converting Enzyme Inhibitors (ACEIs) are chiefly used to manage the hypertensive component of the syndrome. However, recent studies have shown that these drugs may have a role in the non hypertensive aspects of the syndrome as well. Aim: To evaluate the therapeutic effect of enalapril on total body weight, random blood glucose and serum lipid profile in a rodent model of olanzapine induced metabolic syndrome. Materials and Methods: Three different dosages (1 mg/kg/ day, 10 mg/kg/day and 20 mg/kg/day) of oral enalapril were administered (for three weeks) in albino wistar rats, which received prior intra peritoneal olanzapine (for three weeks), and compared against control (normal saline) and standard (olanzapine only and enalapril only) groups. Parameters like total body weight, random blood glucose and serum lipid profile were measured at baseline, at three weeks and at six weeks. Results: Enalapril at 20 mg/kg/day was found to be effective in reversing the weight gain, hyperglycaemia and hypercholesterolaemia, without any changes in triglycerides, High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL). 10 mg/kg/day of enalapril prevented any further rise in body weight, blood glucose, total cholesterol and serum triglycerides, after olanzapine was stopped. 1 mg/kg/day of enalapril was ineffective. Conclusion: High dose of enalapril may be considered as a component of therapeutic regimens to combat weight gain, hyperglycaemia and dyslipidaemia seen in metabolic syndrome, in addition to its antihypertensive utility. Further rodent and clinical studies may be required to ascertain the same.

Original languageEnglish
Pages (from-to)FF01-FF06
JournalJournal of Clinical and Diagnostic Research
Volume11
Issue number2
DOIs
Publication statusPublished - 01-02-2017

Fingerprint

olanzapine
Enalapril
Therapeutic Uses
Wistar Rats
Rats
Blood Glucose
Body Weight
Hyperglycemia
Weight Gain
Rodentia
Triglycerides
Serum
Lipids
HDL Lipoproteins
Medical problems
Dyslipidemias
Hypercholesterolemia
LDL Lipoproteins
Angiotensin-Converting Enzyme Inhibitors
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

Arivazhahan, Avinash ; Bairy, Laxminarayana Kurady ; Nayak, Veena ; Kunder, Sushil Kiran. / A study to assess the therapeutic effect of enalapril on olanzapine induced metabolic syndrome in wistar rats. In: Journal of Clinical and Diagnostic Research. 2017 ; Vol. 11, No. 2. pp. FF01-FF06.
@article{812ca985dee442c2ab6a46a359e63b49,
title = "A study to assess the therapeutic effect of enalapril on olanzapine induced metabolic syndrome in wistar rats",
abstract = "Introduction: Metabolic Syndrome (MS) is a complex of risk factors for the development of cardiovascular complications and Type 2 Diabetes Mellitus (DM). Pharmacological management of the condition is complex, as multiple drug groups have to be used, as the syndrome itself is multi faceted. Angiotensin Converting Enzyme Inhibitors (ACEIs) are chiefly used to manage the hypertensive component of the syndrome. However, recent studies have shown that these drugs may have a role in the non hypertensive aspects of the syndrome as well. Aim: To evaluate the therapeutic effect of enalapril on total body weight, random blood glucose and serum lipid profile in a rodent model of olanzapine induced metabolic syndrome. Materials and Methods: Three different dosages (1 mg/kg/ day, 10 mg/kg/day and 20 mg/kg/day) of oral enalapril were administered (for three weeks) in albino wistar rats, which received prior intra peritoneal olanzapine (for three weeks), and compared against control (normal saline) and standard (olanzapine only and enalapril only) groups. Parameters like total body weight, random blood glucose and serum lipid profile were measured at baseline, at three weeks and at six weeks. Results: Enalapril at 20 mg/kg/day was found to be effective in reversing the weight gain, hyperglycaemia and hypercholesterolaemia, without any changes in triglycerides, High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL). 10 mg/kg/day of enalapril prevented any further rise in body weight, blood glucose, total cholesterol and serum triglycerides, after olanzapine was stopped. 1 mg/kg/day of enalapril was ineffective. Conclusion: High dose of enalapril may be considered as a component of therapeutic regimens to combat weight gain, hyperglycaemia and dyslipidaemia seen in metabolic syndrome, in addition to its antihypertensive utility. Further rodent and clinical studies may be required to ascertain the same.",
author = "Avinash Arivazhahan and Bairy, {Laxminarayana Kurady} and Veena Nayak and Kunder, {Sushil Kiran}",
year = "2017",
month = "2",
day = "1",
doi = "10.7860/JCDR/2017/24049.9380",
language = "English",
volume = "11",
pages = "FF01--FF06",
journal = "Journal of Clinical and Diagnostic Research",
issn = "2249-782X",
publisher = "Journal of Clinical and Diagnostic Research",
number = "2",

}

A study to assess the therapeutic effect of enalapril on olanzapine induced metabolic syndrome in wistar rats. / Arivazhahan, Avinash; Bairy, Laxminarayana Kurady; Nayak, Veena; Kunder, Sushil Kiran.

In: Journal of Clinical and Diagnostic Research, Vol. 11, No. 2, 01.02.2017, p. FF01-FF06.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A study to assess the therapeutic effect of enalapril on olanzapine induced metabolic syndrome in wistar rats

AU - Arivazhahan, Avinash

AU - Bairy, Laxminarayana Kurady

AU - Nayak, Veena

AU - Kunder, Sushil Kiran

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Introduction: Metabolic Syndrome (MS) is a complex of risk factors for the development of cardiovascular complications and Type 2 Diabetes Mellitus (DM). Pharmacological management of the condition is complex, as multiple drug groups have to be used, as the syndrome itself is multi faceted. Angiotensin Converting Enzyme Inhibitors (ACEIs) are chiefly used to manage the hypertensive component of the syndrome. However, recent studies have shown that these drugs may have a role in the non hypertensive aspects of the syndrome as well. Aim: To evaluate the therapeutic effect of enalapril on total body weight, random blood glucose and serum lipid profile in a rodent model of olanzapine induced metabolic syndrome. Materials and Methods: Three different dosages (1 mg/kg/ day, 10 mg/kg/day and 20 mg/kg/day) of oral enalapril were administered (for three weeks) in albino wistar rats, which received prior intra peritoneal olanzapine (for three weeks), and compared against control (normal saline) and standard (olanzapine only and enalapril only) groups. Parameters like total body weight, random blood glucose and serum lipid profile were measured at baseline, at three weeks and at six weeks. Results: Enalapril at 20 mg/kg/day was found to be effective in reversing the weight gain, hyperglycaemia and hypercholesterolaemia, without any changes in triglycerides, High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL). 10 mg/kg/day of enalapril prevented any further rise in body weight, blood glucose, total cholesterol and serum triglycerides, after olanzapine was stopped. 1 mg/kg/day of enalapril was ineffective. Conclusion: High dose of enalapril may be considered as a component of therapeutic regimens to combat weight gain, hyperglycaemia and dyslipidaemia seen in metabolic syndrome, in addition to its antihypertensive utility. Further rodent and clinical studies may be required to ascertain the same.

AB - Introduction: Metabolic Syndrome (MS) is a complex of risk factors for the development of cardiovascular complications and Type 2 Diabetes Mellitus (DM). Pharmacological management of the condition is complex, as multiple drug groups have to be used, as the syndrome itself is multi faceted. Angiotensin Converting Enzyme Inhibitors (ACEIs) are chiefly used to manage the hypertensive component of the syndrome. However, recent studies have shown that these drugs may have a role in the non hypertensive aspects of the syndrome as well. Aim: To evaluate the therapeutic effect of enalapril on total body weight, random blood glucose and serum lipid profile in a rodent model of olanzapine induced metabolic syndrome. Materials and Methods: Three different dosages (1 mg/kg/ day, 10 mg/kg/day and 20 mg/kg/day) of oral enalapril were administered (for three weeks) in albino wistar rats, which received prior intra peritoneal olanzapine (for three weeks), and compared against control (normal saline) and standard (olanzapine only and enalapril only) groups. Parameters like total body weight, random blood glucose and serum lipid profile were measured at baseline, at three weeks and at six weeks. Results: Enalapril at 20 mg/kg/day was found to be effective in reversing the weight gain, hyperglycaemia and hypercholesterolaemia, without any changes in triglycerides, High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL). 10 mg/kg/day of enalapril prevented any further rise in body weight, blood glucose, total cholesterol and serum triglycerides, after olanzapine was stopped. 1 mg/kg/day of enalapril was ineffective. Conclusion: High dose of enalapril may be considered as a component of therapeutic regimens to combat weight gain, hyperglycaemia and dyslipidaemia seen in metabolic syndrome, in addition to its antihypertensive utility. Further rodent and clinical studies may be required to ascertain the same.

UR - http://www.scopus.com/inward/record.url?scp=85011818903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011818903&partnerID=8YFLogxK

U2 - 10.7860/JCDR/2017/24049.9380

DO - 10.7860/JCDR/2017/24049.9380

M3 - Article

VL - 11

SP - FF01-FF06

JO - Journal of Clinical and Diagnostic Research

JF - Journal of Clinical and Diagnostic Research

SN - 2249-782X

IS - 2

ER -